Status:
TERMINATED
Study Evaluating GAP-486 in Heart Rhythm
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Arrhythmia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
Eligibility Criteria
Inclusion
- Patients undergoing an electrophysiology study for evaluation of heart rhythm.
Exclusion
- Patients with uncontrolled blood pressure
- Patients with certain cardiac risk factors
- Patients with significant kidney or liver problems
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00137293
Start Date
November 1 2005
End Date
October 1 2006
Last Update
December 10 2007
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco, California, United States, 94143
2
Washington D.C., District of Columbia, United States, 20010
3
Hershey, Pennsylvania, United States, 17033
4
Ottawa, Ontario, Canada, K1Y 4W7